These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 11841346)

  • 1. Urokinase as a multidomain protein and polyfunctional cell regulator.
    Stepanova VV; Tkachuk VA
    Biochemistry (Mosc); 2002 Jan; 67(1):109-18. PubMed ID: 11841346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation.
    Tarui T; Akakura N; Majumdar M; Andronicos N; Takagi J; Mazar AP; Bdeir K; Kuo A; Yarovoi SV; Cines DB; Takada Y
    Thromb Haemost; 2006 Mar; 95(3):524-34. PubMed ID: 16525582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors of the protease domain of urokinase-type plasminogen activator.
    Rockway TW; Nienaber V; Giranda VL
    Curr Pharm Des; 2002; 8(28):2541-58. PubMed ID: 12369939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Domain-domain interactions in hybrids of tissue-type plasminogen activator and urokinase-type plasminogen activator.
    Bakker AH; Nieuwenbroek NM; Verheijen JH
    Protein Eng; 1995 Dec; 8(12):1295-1302. PubMed ID: 8869642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urokinase-type plasminogen activator.
    Crippa MP
    Int J Biochem Cell Biol; 2007; 39(4):690-4. PubMed ID: 17118695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction between kringle and growth-factor-like domains in the urokinase molecule: possible role in stimulation of chemotaxis.
    Stepanova VV; Beloglazova IB; Gursky YG; Bibilashvily RS; Parfyonova YV; Tkachuk VA
    Biochemistry (Mosc); 2008 Mar; 73(3):252-60. PubMed ID: 18393759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural investigations of recombinant urokinase growth factor-like domain.
    Beloglazova IB; Beabealashvilli RSh; Gursky YG; Bocharov EV; Mineev KS; Parfenova EV; Tkachuk VA
    Biochemistry (Mosc); 2013 May; 78(5):517-30. PubMed ID: 23848154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasmin-dependent elimination of the growth-factor-like domain in urokinase causes its rapid cellular uptake and degradation.
    Poliakov A; Tkachuk V; Ovchinnikova T; Potapenko N; Bagryantsev S; Stepanova V
    Biochem J; 2001 May; 355(Pt 3):639-45. PubMed ID: 11311125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cleavage of pro-urokinase type plasminogen activator by stromelysin-1.
    Orgel D; Schröder W; Hecker-Kia A; Weithmann KU; Kolkenbrock H; Ulbrich N
    Clin Chem Lab Med; 1998 Sep; 36(9):697-702. PubMed ID: 9804393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The crystal structure of the catalytic domain of human urokinase-type plasminogen activator.
    Spraggon G; Phillips C; Nowak UK; Ponting CP; Saunders D; Dobson CM; Stuart DI; Jones EY
    Structure; 1995 Jul; 3(7):681-91. PubMed ID: 8591045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure of human urokinase plasminogen activator in complex with its receptor.
    Huai Q; Mazar AP; Kuo A; Parry GC; Shaw DE; Callahan J; Li Y; Yuan C; Bian C; Chen L; Furie B; Furie BC; Cines DB; Huang M
    Science; 2006 Feb; 311(5761):656-9. PubMed ID: 16456079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor.
    Ploug M
    Curr Pharm Des; 2003; 9(19):1499-528. PubMed ID: 12871065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amino-terminal fragment of urokinase-type plasminogen activator inhibits its plasminogen activation.
    Sun Z; Zhang PX; Wang P; Gurewich V; Shen HY; Liu JN
    Thromb Res; 2002 Apr; 106(2):105-11. PubMed ID: 12182908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation and role of urokinase plasminogen activator in vascular remodelling.
    Tkachuk V; Stepanova V; Little PJ; Bobik A
    Clin Exp Pharmacol Physiol; 1996 Sep; 23(9):759-65. PubMed ID: 8911711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor.
    Lijnen HR; De Cock F; Collen D
    Eur J Biochem; 1994 Sep; 224(2):567-74. PubMed ID: 7925373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unfolding studies of the protease domain of urokinase-type plasminogen activator: the existence of partly folded states and stable subdomains.
    Nowak UK; Cooper A; Saunders D; Smith RA; Dobson CM
    Biochemistry; 1994 Mar; 33(10):2951-60. PubMed ID: 8130209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
    Vines DJ; Lee SW; Dichek DA; Ellis V
    J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
    Plesner T; Behrendt N; Ploug M
    Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urokinase Type Plasminogen Activator and the Molecular Mechanisms of its Regulation in Cancer.
    Santibanez JF
    Protein Pept Lett; 2017; 24(10):936-946. PubMed ID: 28820062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the zymogen to urokinase-type plasminogen activator is associated with increased interdomain flexibility.
    Behrens MA; Botkjaer KA; Goswami S; Oliveira CL; Jensen JK; Schar CR; Declerck PJ; Peterson CB; Andreasen PA; Pedersen JS
    J Mol Biol; 2011 Aug; 411(2):417-29. PubMed ID: 21669207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.